Human DYRK1B adenoviral particles

The dual-specificity tyrosine-regulated kinase 1B (DYRK1B) gene encodes a serine/threonine protein kinase belonging to the DYRK family that plays a key role in cell proliferation, differentiation, and survival. DYRK1B has attracted particular attention due to its involvement in metabolic regulation, cell cycle control, and stress response pathways. Studies have shown that DYRK1B overexpression is associated with a variety of cancers, including pancreatic and ovarian cancers, where it promotes tumor growth by inhibiting apoptosis and promoting cell cycle progression. In addition, DYRK1B has been associated with insulin resistance and metabolic syndrome, making it a potential therapeutic target for metabolic disorders. The kinase is able to phosphorylate a variety of substrates, including transcription factors and cell cycle regulators. Understanding the molecular mechanisms of DYRK1B is essential for the development of targeted therapies for cancer and metabolic diseases. Human DYRK1B adenoviral particles are genetically engineered viral vectors designed to deliver the DYRK1B gene to target cells for research applications. Based on adenoviral technology, these particles achieve high transduction efficiencies in a variety of cell types, including dividing and non-dividing cells. Researchers use these particles to overexpress DYRK1B in vitro or in vivo to explore its effects on signaling pathways, cell cycle dynamics, and metabolic regulation. To ensure safety, these particles are typically non-replicating and are produced under strict quality controls to ensure high titer and purity. Applications include functional genomics, drug screening, and mechanistic studies in cancer biology and metabolic research. By providing a powerful tool to modulate DYRK1B expression, these adenoviral particles accelerate the discovery of disease mechanisms and therapeutic approaches.